<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716712</url>
  </required_header>
  <id_info>
    <org_study_id>20-32979</org_study_id>
    <nct_id>NCT04716712</nct_id>
  </id_info>
  <brief_title>Infant Mortality Reduction by the Mass Administration of Azithromycin</brief_title>
  <acronym>MIRAMA</acronym>
  <official_title>Mortalite Infantile Reduite Par l'Administration de Masse de l'Azitromycine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helen Keller International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche en Sante de Nouna, Burkina Faso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will investigate the supplementation of azithromycin distribution to the &quot;Child&#xD;
      Health Days&quot; platform in Burkina Faso for child mortality reduction. This distribution will&#xD;
      pair door-to-door administration of vitamin A and azithromycin or placebo with acute&#xD;
      malnutrition screening among children 1-11 months old.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MORDOR clinical trial funded by the Bill &amp; Melinda Gates Foundation in Malawi, Tanzania,&#xD;
      and Niger demonstrated that biannual oral azithromycin distributions to children aged 1-59&#xD;
      months significantly reduced child mortality. The investigators hypothesize that biannual&#xD;
      administration of azithromycin to children aged 1-11 months will reduce mortality in this age&#xD;
      group. The aim of the project is to demonstrate that this intervention can be scaled up and&#xD;
      produce the same benefits on mortality as those documented in smaller, more controlled&#xD;
      studies. Since 1986, to reduce child mortality, Burkina Faso has been administering high-dose&#xD;
      vitamin A supplementation to children aged 6-59 months on a biannual basis through the &quot;Child&#xD;
      Health Days&quot; platform. The &quot;Child Health days&quot; are a door-to-door distribution of vitamin A&#xD;
      coupled with screening for acute malnutrition in children aged 6-59 months and deworming of&#xD;
      children aged 12-59 months. This approach has been successful but expensive. A new strategy&#xD;
      implemented since September 2017 relies on community-based health workers (CBHWs) to&#xD;
      distribute Vitamin A in rural areas, and on community-based distributors (CDs) in urban&#xD;
      areas. Based on expert opinion and the preliminary findings of formative research conducted&#xD;
      by the Ministry of Health and Helen Keller International, it was agreed that the Child Health&#xD;
      Days platform was the most appropriate platform to implement the biannual administration of&#xD;
      azithromycin to children aged 1 to 11 months.&#xD;
&#xD;
      In this trial, mortality will be measured via complete birth history which will be collected&#xD;
      in a subset of villages in the study area before the first treatment distribution. The study&#xD;
      team will also conduct a baseline census of the study areas for treatment coverage&#xD;
      estimations.&#xD;
&#xD;
      Sixty villages (30 azithromycin, 30 placebo) will contribute to the macrolide resistance&#xD;
      outcomes, where the study team will collect rectal and nasal swabs from children 1-59 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 4, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>The study will be a double-blind, placebo-controlled, cluster-randomized trial in which health centers (CSPS) in the 3 intervention regions will be randomized to either CHD combined with placebo (33%) or CHD combined with Azithromycin (67%), an allocation of 1:2 that favors active treatment. The allocation sequence and treatment labels will be masked to all but one biostatistician and one analyst at UCSF. The placebo will be indistinguishable from the active azithromycin.&#xD;
Antimicrobial resistance will be monitored in a parallel study of communities from the target study area. 60 communities will be randomly selected among eligible communities, and randomized in a 1 : 1 fashion to CHD+placebo or CHD+azithromycin</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This will be a quadruple blinded study. Only one biostatistician and one analyst at UCSF will have the unmasking information.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>24 months following baseline</time_frame>
    <description>All-cause mortality among children aged 1-11 months 24 months after baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macrolide resistant pneumococcus</measure>
    <time_frame>24 months</time_frame>
    <description>Prevalence of macrolide-resistant pneumococcus from nasopharyngeal swabs in children 1-59 months old 24 months after baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic determinant macrolide resistance</measure>
    <time_frame>24 months</time_frame>
    <description>Load of genetic determinants of resistance to macrolides from rectal swabs in children 1-59 months old 24 months after baseline</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">694400</enrollment>
  <condition>Child Mortality</condition>
  <arm_group>
    <arm_group_label>Biannual mass oral azithromycin + child health days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bi-annual Mass Azithromycin distribution to all children 1-11 months old in participating communities paired with the Child Health Days Vitamin A distribution platform</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biannual mass placebo + child health days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bi-annual Mass placebo distribution to all children 1-11 months old in participating communities paired with the Child Health Days Vitamin A distribution platform</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resistance Sub Study: Azithromycin + Child Health Days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antimicrobial resistance will be monitored in a parallel study of communities from the target study area. 60 communities will be randomly selected among eligible communities, and randomized in a 1 : 1 fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resistance Sub Study: Placebo + Child Health Days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Antimicrobial resistance will be monitored in a parallel study of communities from the target study area. 60 communities will be randomly selected among eligible communities, and randomized in a 1 : 1 fashion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.</description>
    <arm_group_label>Biannual mass oral azithromycin + child health days</arm_group_label>
    <arm_group_label>Resistance Sub Study: Azithromycin + Child Health Days</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching identical placebo in packaging, appearance, and taste.</description>
    <arm_group_label>Biannual mass placebo + child health days</arm_group_label>
    <arm_group_label>Resistance Sub Study: Placebo + Child Health Days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Community eligibility criteria:&#xD;
&#xD;
          -  Located in one of the three selected regions: SudOuest, Centre-Ouest, Hauts-Bassins&#xD;
&#xD;
          -  Verbal consent of the community leader is obtained&#xD;
&#xD;
        Inclusion criteria for children:&#xD;
&#xD;
          -  Aged 1 to 11 months&#xD;
&#xD;
          -  Living in one of the communities participating in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Community exclusion criteria:&#xD;
&#xD;
        • Inaccessible or unsafe for the study team&#xD;
&#xD;
        Exclusion criteria for children:&#xD;
&#xD;
        • Known allergy to macrolides&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>11 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Lietman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fanny Fyago Wienne</last_name>
    <phone>+226 25 36 00 23/30</phone>
    <email>fyago-wienne@hki.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tom Lietman, MD</last_name>
    <email>tom.lietman@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tom Lietman, MD</last_name>
      <email>tom.lietman@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche en Sante de Nouna</name>
      <address>
        <city>Nouna</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <contact>
      <last_name>Ali Sie, MD</last_name>
      <email>sieali@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helen Keller International</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <contact>
      <last_name>Fanny Yago Wienne</last_name>
      <email>fyago-wienne@hki.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, Kalua K, Mrango Z, Ray KJ, Cook C, Lebas E, O'Brien KS, Emerson PM, Porco TC, Lietman TM; MORDOR Study Group. Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. N Engl J Med. 2018 Apr 26;378(17):1583-1592. doi: 10.1056/NEJMoa1715474.</citation>
    <PMID>29694816</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Azithromycin</keyword>
  <keyword>Mass Drug Administration</keyword>
  <keyword>Child Mortality</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

